

Docket No.: C2432.0060
(PATENT)

Express Mail Label No.: EV 262 741 419 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bengt Herslöf et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: ANTICOAGULANT COMPOSITION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

☒ This IDS is being filed before the First Office Action¹.

Copies of Information:

☒ Copies of the cited ISR documents are not enclosed as they were provided by the International Bureau.

¹ The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

Application No.: Not Yet Assigned

Docket No.: C2432.0060
 Express Mail Label No.: EV 262 741 419 US

Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: December 3, 2004

Respectfully submitted,

By Edward A. Meilman
 Edward A. Meilman
 Registration No.: 24,735
 DICKSTEIN SHAPIRO MORIN &
 OSHINSKY LLP
 1177 Avenue of the Americas
 New York, New York 10036-2714
 (212) 835-1400
 Attorney for Applicant

EAM/da

| | | | | | |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | Not Yet Assigned |
| | | | | Filing Date | Concurrently Herewith |
| | | | | First Named Inventor | Bengt Herslöf |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | C2432.0060 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AA | US-6,626,869 | 05-06-1997 | Nyqvist Hakan, et al. | |
| | AB | US-5,082,667 | 01-21-1992 | Kurt G. Van Scoik | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|---|--|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | | |
| | BA | WO-92/05771-A1 | | 04-16-1992 | KABI PHARMACIA AB | | |
| | BB | EP-0368247-A2 | | 05-16-1990 | TAKEDA CHEMICAL INDUSTRIES, LTD. | | |
| | BC | WO-03/49721-A1 | | 06-19-2003 | COSMO S.P.A. | | |
| | BD | WO-02/47663-A1 | | 06-20-2002 | F. HOFFMAN-LA ROCHE AG | | |
| | BE | WO-01/91729-A1 | | 12-06-2001 | BASF AKTIENGESELLSCHAFT | | |
| | BF | WO-93/19737-A1 | | 10-14-1993 | KABI PHARMACIA AB | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CA | European Journal of Pharmaceutical Sciences, Volume 1, 1994, L. Lohikangas et al.; "Relative contribution of phosphatidylcholine and monoglyceride to absorption enhancement of low molecular weight heparin (Fragmin) by a new lipid-based drug delivery system in monolayers of human intestinal epithelial Caco-2 cells and after rectal administration to rabbits"; pp. 307 - 312, abstract 3.1, 3.3, discussion | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|